# OnCo record nct02767804 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02767804/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02767804", "NCT02767804" ;
  schema:name "eXalt3"@en ;
  schema:alternateName "X396-CLI-301"@en, "eXALT3"@en, "eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients"@en ;
  schema:description "eXalt3 showed that ensartinib, a second-generation ALK pill, kept ALK-positive lung cancer under control about twice as long as crizotinib, with useful activity against brain metastases."@en ;
  schema:url <https://onco.cc/trials/nct02767804/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02767804>, <https://doi.org/10.1001/jamaoncol.2021.3523>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2016-06" ;
  onco:related <https://onco.cc/trials/alex/>, <https://onco.cc/trials/alta-1l/>, <https://onco.cc/trials/crown/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/ensartinib/>, <https://onco.cc/drugs/crizotinib/> ;
  onco:companies <https://onco.cc/companies/xcovery/> ;
  onco:terms <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/tki-term/> ;
  onco:people <https://onco.cc/people/tony-mok/>, <https://onco.cc/people/martin-reck/>, <https://onco.cc/people/heather-wakelee/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct02767804-jama-oncol-2021/> .